Safety and Immunogenicity First-in-human Dose-ranging Study of Self-Amplifying RNA Seasonal Influenza Vaccine in Adults

NCT06125691 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

139

Enrollment

INDUSTRY

Sponsor class

Conditions

Influenza, Human

Interventions

BIOLOGICAL: ARCT-2138
BIOLOGICAL: Licensed Quadrivalent Vaccine for younger adults
BIOLOGICAL: Licensed Quadrivalent Vaccine for older adults

Sponsor

Arcturus Therapeutics, Inc.

Collaborators

[object Object]
[object Object]